Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age (Q24194589)

1

object named as

Martina Penazzato

0 references

Andrew Prendergast

2

object named as

Andrew J. Prendergast

0 references

author name string

Lulu M Muhe

3

0 references

Denis Tindyebwa

Cochrane Database of Systematic Reviews

4

0 references

publication date

22 May 2014

0 references

published in

0 references

cites work

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Antiretroviral treatment for children with peripartum nevirapine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Early Antiretroviral Therapy and Mortality among HIV-Infected Infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

A trial of three antiretroviral regimens in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

CD4 cell count criteria to determine when to initiate antiretroviral therapy in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Treatment of young children with HIV infection: using evidence to inform policymakers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

Current CD4 Cell Count and the Short‐Term Risk of AIDS and Death before the Availability of Effective Antiretroviral Therapy in HIV‐Infected Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

inferred from DOI database lookup

7 January 2021

based on heuristic

Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4

inferred from DOI database lookup

7 January 2021

based on heuristic

Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004772.PUB4